Ensitrelvir reduced transmission of SARS-CoV-2 by 67% when given to uninfected household contacts of a person with COVID-19 ...

Maze Therapeutics IPOs at $487M, targeting APOL1 Kidney Disease with MZE829 in Phase 2. Click here to read an analysis of MAZE stock now.

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir ...

Apnimed, Inc., a pharmaceutical company focused on discovering, developing, and commercializing first-in-class oral therapies for the neuromuscular dysfunction associated with obstructive sleep apnea ...

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements ...

Akimasa Fukushi, M.D., of Shionogi & Co., Ltd, in Osaka, Japan, and colleagues randomly assigned household contacts (HHC) of ...

Made by Japanese pharmaceutical firm Shionogi, ensitrelvir is approved in Japan for the treatment of mild to moderate ...

Made by Japanese pharmaceutical firm Shionogi, ensitrelvir is approved in Japan for the treatment of mild to moderate ...

But what if you could avoid getting COVID-19 altogether? That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific conference in San ...

Oral ensitrelvir was significantly more effective than placebo for preventing COVID-19 infection in uninfected at-risk adults and adolescents who had exposure to those infected, based on data from ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company's EMBRACE phase IIb study. 1 The ...

API R&D Laboratory, Pharmaceutical Technology Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-Chome, Toyonaka, Osaka 561-0825, Japan ...